Parent and Guardian Opinions on Obesity Medications Use in Adolescents with Obesity and Related Comorbidities.

Autor:	Raatz S; Department of Pediatrics, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.; Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA., Freese RL; Clinical and Translational Science Institute, Biostatistical Design and Analysis Center, University of Minnesota, Minneapolis, Minnesota, USA., Jang S; Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA.; Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis, Minnesota, USA., Kunin-Batson A; Department of Pediatrics, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.; Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA., Gross AC; Department of Pediatrics, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.; Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA., Bensignor MO; Department of Pediatrics, Medical School, University of Minnesota, Minneapolis, Minnesota, USA.; Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Jazyk:	angličtina
Zdroj:	Childhood obesity (Print) [Child Obes] 2024 Dec 18. Date of Electronic Publication: 2024 Dec 18.
DOI:	10.1089/chi.2024.0351
Abstrakt:	Background: There are now four FDA-approved anti-obesity medications (AOMs) for youth ≥12 years, which can be effective therapies to treat obesity and obesity-related comorbidities. Objectives: This study describes parent/guardian (caregiver) openness to using AOMs for adolescents with obesity and evaluates factors that may contribute to openness. Methods: Caregivers of adolescents aged 12-17 years were surveyed. Self-reported height, weight, demographic information, family, and personal history of obesity or obesity-related comorbidities were collected. Participants rated their openness to starting an AOM for their child for obesity alone or obesity-related comorbidities on a 7-point Likert scale. A Likert rating of less than 4 was considered "less open" versus 4-7 was considered "more open." Results: A total of 344 participants completed the survey. Average openness toward AOM use for obesity as the only indication (as opposed to comorbid conditions) was 3.2 ± 1.74. Caregivers who were knowledgeable that the FDA-approved AOM use in adolescents had greater odds of being open to using these medications compared with caregivers who were not knowledgeable (odds ratio: 2.18; 95% confidence interval: 1.25-2.86). Conclusions: Caregivers reported openness to starting an AOM if they had prior knowledge of these medications, highlighting the need for family education on AOM use and indications.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu